750 related articles for article (PubMed ID: 23432783)
1. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
[TBL] [Abstract][Full Text] [Related]
3. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients.
Perfetti V; Colli Vignarelli M; Anesi E; Garini P; Quaglini S; Ascari E; Merlini G
Haematologica; 1999 Mar; 84(3):218-21. PubMed ID: 10189385
[TBL] [Abstract][Full Text] [Related]
4. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
Fernández de Larrea C; Tovar N; Rozman M; Rosiñol L; Aróstegui JI; Cibeira MT; Rovira M; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1084-7. PubMed ID: 21215814
[TBL] [Abstract][Full Text] [Related]
6. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
Hernández-Reyes J; Galo-Hooker E; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
[TBL] [Abstract][Full Text] [Related]
7. AL amyloidosis or multiple myeloma? An important distinction.
Falk RH
Br J Haematol; 2014 Mar; 164(5):748-9. PubMed ID: 24261595
[No Abstract] [Full Text] [Related]
8. AL amyloidosis or multiple myeloma? An important distinction--response to Falk.
Dinner S; Liedtke M
Br J Haematol; 2014 Mar; 164(5):749-50. PubMed ID: 24344936
[No Abstract] [Full Text] [Related]
9. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
Pasqualetti P; Colantonio D; Casale R
Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
[TBL] [Abstract][Full Text] [Related]
10. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.
Joshi R; Horncastle D; Elderfield K; Lampert I; Rahemtulla A; Naresh KN
J Clin Pathol; 2008 Feb; 61(2):213-6. PubMed ID: 17526802
[TBL] [Abstract][Full Text] [Related]
12. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
13. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.
Stifter S; Babarović E; Valković T; Seili-Bekafigo I; Stemberger C; Nacinović A; Lucin K; Jonjić N
Diagn Pathol; 2010 May; 5():30. PubMed ID: 20482792
[TBL] [Abstract][Full Text] [Related]
14. Primary systemic amyloidosis with delayed progression to multiple myeloma.
Rajkumar SV; Gertz MA; Kyle RA
Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
[TBL] [Abstract][Full Text] [Related]
15. Signet-ring plasma cell myeloma.
Grier DD; Robbins K
Am J Hematol; 2012 Jun; 87(6):625. PubMed ID: 21953819
[No Abstract] [Full Text] [Related]
16. [Inclusions fixing thioflavin T in plasmacytes of IgG lambda myeloma with amylosis].
Canioni D; Kermarec J
Arch Anat Cytol Pathol; 1982; 30(5-6):279-83. PubMed ID: 6188417
[No Abstract] [Full Text] [Related]
17. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
[TBL] [Abstract][Full Text] [Related]
18. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
19. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
20. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
